Functional dyspepsia and nonerosive reflux disease: Clinical interactions and their implications

MedGenMed Medscape General Medicine

Volumn 9, Issue 3, 2007, Pages

  Keohane, John ^a   Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; ITOPRIDE; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PAIN THRESHOLD; PATHOPHYSIOLOGY; PREVALENCE; STOMACH DISTENSION; STOMACH EMPTYING; STOMACH FUNDOPLICATION; REVIEW;

DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 34547923182     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol. 2004;18:695-706.
2. Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther. 2006;23:1587-1593.
3. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut. 1999;45(suppl 2):II37-II42.
4. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466-1479.
5. Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ. 2000;162:3-23.
6. Moayyedi P, Talley NJ, Fennerty MB, Vakil N. Can the clinical history distinguish between organic and functional dyspepsia? JAMA. 2006;295:1566-1576.
7. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease--current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-314.
8. Quigley EM. Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol. 2001;13(suppl 1):S13-S18.
9. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920.
10. Tew S, Jamieson GG, Pilowsky I, Myers J. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus. 1997;10:9-15.
11. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion. 1992;51(suppl 1):24-29.
12. Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut. 1998;42:13-16.
13. El-Serag HB, Talley NJ. Systematic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther. 2004;19:643-654.
14. Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol. 1987;22:714-718.
15. Tefera L, Fein M, Ritter MP, et al. Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease? Am Surg. 1997;63:933-936.
16. Locke GR, III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
17. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767-776.
18. Quigley EM, DiBaise JK. Non-erosive reflux disease: the real problem in gastro-oesophageal reflux disease. Dig Liver Dis. 2001;33:523-527.
19. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology. 2004;127:1239-1255.
20. Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 1999;116:515-520.
21. Azpiroz F, Malagelada JR. Physiological variations in canine gastric tone measured by an electronic barostat. Am J Physiol. 1985;248(2 Pt 1):G229-G237.
22. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115:1346-1352.
23. Kim DY, Gado-Aros S, Camilleri M, et al. Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol. 2001;96:3099-3105.
24. Gilja OH, Hausken T, Wilhelmsen I, Berstad A. Impaired accommodation of proximal stomach to a meal in functional dyspepsia. Dig Dis Sci. 1996;41:689-696.
25. Mearin F, Cucala M, Azpiroz F, Malagelada JR. The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology. 1991;101:999-1006.
26. Bouin M, Meunier P, Riberdy-Poitras M, Poitras P. Pain hypersensitivity in patients with functional gastrointestinal disorders: a gastrointestinal-specific defect or a general systemic condition? Dig Dis Sci. 2001;46:2542-2548.
27. Barbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol. 1995;7:1051-1057.
28. Feinle C, Meier O, Otto B, D'Amato M, Fried M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut. 2001;48:347-355.
29. Barbera R, Feinle C, Read NW. Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci. 1995;40:1636-1641.
30. Dent J. Gastro-oesophageal reflux disease. Digestion. 1998;59:433-445.
31. Hopwood D, Milne G, Logan KR. Electron microscopic changes in human oesophageal epithelium in oesophagitis. J Pathol.
32. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology. 1996;111:1200-1205.
33. Fass R, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-1909.
34. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)--acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537-545.
35. Watson RG, Tham TC, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus." Gut. 1997;40:587-590.
36. Cicala M, Emerenziani S, Caviglia R, et al. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease.. Aliment Pharmacol Ther. 2003;18:605-613.
37. Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA. Functional esophageal disorders. Gut. 1999;45(suppl 2):II31-II36.
38. Galmiche JP, Clouse RE, Balint A, et al. Functional esophageal disorders. Gastroenterology. 2006;130:1459-1465.
39. Vu MK, Straathof JW, Schaar PJ, et al. Motor and sensory function of the proximal stomach in reflux disease and after laparoscopic Nissen fundoplication. Am J Gastroenterol. 1999;94:1481-1489.
40. Penagini R, Hebbard G, Horowitz M, et al. Motor function of the proximal stomach and visceral perception in gastro-oesophageal
41. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis. 2000;18:20-26.
42. Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996;10:547-555.
43. Farley A, Wruble LD, Humphries TJ. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. Am J Gastroenterol. 2000;95:1894-1899.
44. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998;12:1055-1065.
45. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol. 2002;37:1395-1402.
46. Bolling-Sternevald E, Lauritsen K, Talley NJ, Junghard O, Glise H. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther. 2003;18:117-124.
47. Hatlebakk JG, Johnsson F, Vilien M, Carling L, Wetterhus S, Thogersen T. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scand J Gastroenterol. 1997;32:1100-1106.
48. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354:832-840.
49. Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999;3:292-300.
50. Eubanks TR, Omelanczuk P, Richards C, Pohl D, Pellegrini CA. Outcomes of laparoscopic antireflux procedures. Am J Surg.
51. Vu MK, Ringers J, Arndt JW, Lamers CB, Masclee AA. Prospective study of the effect of laparoscopic hemifundoplication on motor and sensory function of the proximal stomach. Br J Surg. 2000;87:338-343.
52. Bais JE, Samsom M, Boudesteijn EA, van Rijk PP, Akkermans LM, Gooszen HG. Impact of delayed gastric emptying on the outcome of antireflux surgery. Ann Surg. 2001;234:139-146.